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doi:10.1016/j.jfma.2011.11.010Ketamine hydrochloride, commonly used as a pediatric anesthetic agent, is an N-methyl-D-as-
partic (NMDA) acid receptor antagonist with rapid onset and short duration of action. It
produces a cataleptic-like state where the patient is dissociated from the surrounding environ-
ment by direct action on the cortex and limbic system. It has emerged as an increasingly
popular choice among young drug users, especially within dance club venues. Cases of bladder
dysfunction among recreational ketamine users were reported since Shahani et al first re-
ported nine cases of ketamine-associated ulcerative cystitis in 2007. We report on four
patients who had history of ketamine abuse, presenting with dysuria, fluctuating lower urinary
tract symptoms (LUTS), lower abdominal or perineal pain, and impaired functional bladder
capacities. Urinalysis showed pyuria and microhematuria. Urine culture was sterile. Bladder
ulceration with severe diffuse hemorrhage and low bladder capacity were noted under an-
esthetized cystoscopic examination. Transurethral bladder mucosa biopsy was consistent with
chronic cystitis. Cessation of ketamine abuse was the milestone of treatment, followed by the
administration of mucosal protective agents, such as pentosan polysulphate or hyaluronic
acid. Suprapubic pain was improved in three patients during follow-up. However, the outcome
of treatment depends on the severity of the disease process, similar to that of interstitial
cystitis (IC).
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788 C.-H. Chen et al.Cases of bladder dysfunction among recreational ket-
amine users were reported in succession from literature
since Shahani et al first reported nine cases of ketamine-
associated ulcerative cystitis in 2007.2 We report on four
patients who had a history of ketamine abuse, presenting
with dysuria, fluctuating lower urinary tract symptoms
(LUTS), lower abdominal and/or perineal pain, and severe
bladder dysfunction. Each of the four patients had at
least a 1-year drug abuse history. The relationship
between the occurrence of symptoms and duration of
drug usage was evaluated. We review literature on the
proposed pathophysiologic mechanisms and experimental
observations, which indicate the facilitation of ketamine
in the pathogenesis of neurogenic inflammation of
cystitis.Case report
The first case was a 23-year-old woman, who presented
with recurrent dysuria, frequency, and intermittent lower
abdominal dull pain for 6 months. She had a drug-using
history of ketamine sniffing for 1 year with approximately
three pockets (1 g/pocket) per week. Dysuria was the initial
presentation, which was noted as urethral soreness after
urination. Antibacterial agents were prescribed under the
impression of urinary tract infection, however, dysuria and
frequency relapsed occasionally even under antibiotics
medication. After 12 months of ketamine abuse, persistent
severe LUTS (i.e., frequency, urgency, nocturia and
abdominal pain) developed. She denied other substanceFigure 1 Cystoscopic findings: anesthetized cystoscopy revealed
bladder capacity. (A) Hyperemic lesions; (B) severe post dilation di
(D) bladder perforation.misuse other than cigarette smoking (0.5 pack/day), and
the remainder of her history was unremarkable.
Urinalysis showed red blood cell (RBC) 3e5/high power
field (HPF) and white blood cell (WBC) 3e5/HPF. The urine
culture revealed no growth of bacteria. The functional
bladder capacities obtained from the voiding diary were
10e20 mL/voiding and 30 urinations/day, approximately. A
urodynamic study showed a hypersensitive urinary bladder.
The potassium sensitivity test was positive. Anesthetized
cystoscopy revealed bladder ulceration (Fig. 1), severe
post-dilation hemorrhage, and low bladder capacity. A
transurethral biopsy was performed, and the pathology
revealed neutrophilic and lymphoplasma cell infiltration in
bladder mucosa (Fig. 2), which was consistent with chronic
inflammation. After cystodilation, persistent active
bleeding from the bladder ulcer was noted.
The other three cases presented similar symptoms:
recurrent dysuria, frequency, and intermittent abdominal
pain. Drug-using history and clinical manifestations were
described; details are provided in Tables 1 and 2. Urinalysis
showed only microhematuria and few WBC counts. There
was no bacterial yield from urine culture in any patient.
Functional bladder capacities were almost less than
100 mL. Under anesthetized cystoscopy, severe diffuse
post-dilation hemorrhage, bladder ulceration, and low
bladder capacity were noted (Table 2).
The upper urinary tract evaluated by ultrasonography
showed no hydronephrosis. However, the voiding cystour-
ethrogram revealed bilateral vesicoureteral reflux (Grade I)
in one case (Fig. 3). Non-contrast enhanced abdominal
computed tomography (CT) was performed in one patientbladder ulceration, severe post-dilation hemorrhage, and low
ffuse hemorrhage; (C) bladder ulceration with active bleeding;
Figure 2 Bladder mucosa pathology showed neutrophilic and lymphoplasma cell infiltration in bladder mucosa, which was
consistent with chronic inflammation.
Ketamine-snorting associated cystitis 789due to bladder perforation, which showed a distended
bladder wall with blood clot debris and mild bilateral
hydroureter.
Ketamine abuse cessation was suggested for all patients.
Intravesical instillation with hyaluronic acid (Cystistat)Table 1 Drug-using history.
Patient no. Sex/age (years) Duration of drug
inhalation (months)
In
an
1 23/F 12 12
2 24/F 12 12
3 20/M 12 6
4 24/F 12 12
a One pocket weighs approximately 1 g.
Table 2 Clinical manifestation and cystoscopic findings.
Patient no. Urinanalysis Urine
culture
Urodynamic
functional
capacity (mL)
Hyp
les
1 WBC 3e5/HP
RBC 3e5/HP
Sterile 26 þ
2 WBC 0e2/HP
RBC 6e10/HP
Sterile 59 þ
3 WBC 3e5/HP
RBC 0e2/HP
Sterile 68 þ
4 WBC 30e50/HP
RBC 3e5/HP
Sterile a þ
a Unavailable due to severe pain during catheterization in urodynam
b Unmeasurable due to perforation.was performed in three patients. Oral agent with pentosan
polysulphate (Elmiron) was prescribed for one patient due
to intolerability of bladder instillation. Improvement of
suprapubic pain for all three patients was noted during
follow-up.terval between taking ketamine
d cystitis development (months)
Drug dosage (pockets)a
Three/week
Three/month
Three/week
Three/week
eremic
ions
Ulceration Severe
post-dilation
hemorrhage
Secondary maximal
capacity under
anesthesia (mL)
e Focal 180
þ Focal 210
e Diffuse 155
þ Diffuse b
ic study.
Figure 3 Bilateral vesicoureteral reflux by voiding cystourethrogram.
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Adverse reactions among recreational ketamine abusers
have been found to influence the nervous and cardiopul-
monary systems. Little was known about the association
between ketamine abuse and cystitis. Ketamine is metab-
olized in the liver to an active metabolite, norketamine,
which has approximately a third the potency of ketamine.
Ketamine metabolites are then excreted by the kidney with
an elimination half-life of 2e3 hours in adults.3 All of our
patients denied using other illicit drugs. Personal reports
revealed no additional substances likely to cause this
disease.
High quantities of ketamine and its metabolite, norket-
amine, can be measured in the urine of patients using ket-
amine.4 Literatures of case reports concerning ketamine-
induced cystitis postulated that its etiology might be the
direct toxic effect of ketamine and its active metabolite on
bladder mucosa.2,5 The actual mechanism is still unclear. In
our patients, there was no correlation between drug
administration dosage and duration and severity of symp-
toms. At present, to our knowledge, no papers reported the
relationship between dosage and symptoms.
Chu et al reported 10 cases of ketamine abuse-induced
cystitis, eight of them presented with impaired renal
function test and bilateral hydronephrosis by ultrasonog-
raphy.5 None of our patients had hydronephrosis, however,
two of them had severe constricted bladder with bilateral
lower hydroureter. Abdominal CT also showed mild bilateral
hydroureter in one of our patients. Further evaluation by
voiding cystourethrogram showed bilateral vesicoureteral
reflux in one patient. This may imply damage of the anti-
reflux function of vesicoureteral valves due to severe con-
stricted bladder. We suggest that upper urinary tract
evaluation should be performed, especially in patients who
have impaired renal function test or severe constricted
urinary bladder.
Symptoms and signs among ketamine users are similar to
that of patients diagnosedwith interstitial cystitis (IC),which
is frequency, nocturia, intermittent lower abdominal pain,
impaired functional capacity, and post cystodilationhemorrhage. Several pathophysiologicmechanisms including
epithelial dysfunction, mast cell activation, and neurogenic
inflammation have been proposed. Bladder epithelial
dysfunction with urinary absolute leakage, mast cell
degranulation with vasoactive response and mediators,
substance P release, and activation or sensitization of
mechanoreceptors or chemoreceptors contribute to the
progression of bladder injury.6
Experimental evidence showed a central role for
substance P and neurokinin-1 receptor in cystitis. Bladder
biopsies from IC patients present increased density of
neurokinin-1 receptors, nerves, and substance P-containing
fibers.7 We deduce that nociceptive responses following
nociceptor stimulation would be reduced by NMDA antag-
onists because there are many reports that glutamate
neurons and NMDA receptors play important roles in pain
transmission. However, the opposite situation, where
nociceptive responses induced by substance P were
enhanced by NMDA antagonists, was also demonstrated.8
This may suggest the facilitation of ketamine in patho-
genesis of neurogenic inflammation of cystitis. Other
evidence indicated that the inflammatory process related
to bladder dysfunction included eosinophilic infiltration
over bladder mucosa, similar to allergic cystitis.2 The
immunologic pathology of ketamine cystitis was suspected
following elevated erythrocyte sedimentation rate (ESR)
and serum complements C3 and C4 in a serum chemistry
test.9
In young adults presenting with severe lower urinary
dysfunction, this new form of uropathy and its relation to
ketamine abuse should always be considered. The real
proportion of cystitis in ketamine users needs further
investigation in order to determine the actual association
between ketamine administration and cystitis. Therapy
options should include cessation of drug abuse and hep-
arinoid therapy.2 Oral pentosan polysulphate or intravesical
hyaluronic acid treatment may be reasonable choices.2 In
addition, substance misuse is a public health issue; patients
who abuse drugs always have psychological comorbidity,
therefore multidisciplinary care within a biopsychosocial
model would be helpful for further management of these
Ketamine-snorting associated cystitis 791patients. The outcome of treatment depends on the
severity of the disease process, similar to that of IC.
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